JP2016506945A - 第ｘ因子変異体 - Google Patents

第ｘ因子変異体 Download PDF

Info

Publication number
JP2016506945A
JP2016506945A JP2015555777A JP2015555777A JP2016506945A JP 2016506945 A JP2016506945 A JP 2016506945A JP 2015555777 A JP2015555777 A JP 2015555777A JP 2015555777 A JP2015555777 A JP 2015555777A JP 2016506945 A JP2016506945 A JP 2016506945A
Authority
JP
Japan
Prior art keywords
seq
factor
sequence
family
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015555777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506945A5 (OSRAM
Inventor
ジャン−リュック・プランティエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2016506945A publication Critical patent/JP2016506945A/ja
Publication of JP2016506945A5 publication Critical patent/JP2016506945A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2015555777A 2013-02-04 2014-02-03 第ｘ因子変異体 Ceased JP2016506945A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1350930 2013-02-04
FR1350930A FR3001729B1 (fr) 2013-02-04 2013-02-04 Mutants du facteur x
PCT/FR2014/050191 WO2014118481A1 (fr) 2013-02-04 2014-02-03 Mutants du facteur x

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018213037A Division JP2019050819A (ja) 2013-02-04 2018-11-13 第ｘ因子変異体

Publications (2)

Publication Number Publication Date
JP2016506945A true JP2016506945A (ja) 2016-03-07
JP2016506945A5 JP2016506945A5 (OSRAM) 2017-02-23

Family

ID=48083383

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555777A Ceased JP2016506945A (ja) 2013-02-04 2014-02-03 第ｘ因子変異体
JP2018213037A Pending JP2019050819A (ja) 2013-02-04 2018-11-13 第ｘ因子変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018213037A Pending JP2019050819A (ja) 2013-02-04 2018-11-13 第ｘ因子変異体

Country Status (13)

Country Link
US (1) US10364424B2 (OSRAM)
EP (1) EP2951297B1 (OSRAM)
JP (2) JP2016506945A (OSRAM)
KR (1) KR101942619B1 (OSRAM)
CN (1) CN104995297B (OSRAM)
AU (1) AU2014210986A1 (OSRAM)
CA (1) CA2900010A1 (OSRAM)
DK (1) DK2951297T3 (OSRAM)
ES (1) ES2636162T3 (OSRAM)
FR (1) FR3001729B1 (OSRAM)
IL (1) IL239889A0 (OSRAM)
MX (1) MX2015009867A (OSRAM)
WO (1) WO2014118481A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019050819A (ja) * 2013-02-04 2019-04-04 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 第ｘ因子変異体
JP2019521324A (ja) * 2016-05-13 2019-07-25 ザ・スクリップス・リサーチ・インスティテュートＴｈｅ Ｓｃｒｉｐｐｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗血栓療法および止血療法のための組成物および方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506090A (ja) * 1992-01-03 1995-07-06 オクラホマ メディカル リサーチ ファウンデーション 組換え可溶性組織因子の発現および精製
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
WO2001010896A2 (en) * 1999-08-10 2001-02-15 Baxter Aktiengesellschaft Factor x analog with an improved ability to be activated
JP2001513631A (ja) * 1997-02-27 2001-09-04 バクスター・アクチエンゲゼルシャフト 修飾されたプロテアーゼ切断部位を有するｘ因子類似体
JP2005506086A (ja) * 2001-10-19 2005-03-03 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル トロンビン切断性キメラタンパク質
JP2006507806A (ja) * 2002-07-03 2006-03-09 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル トロンビン切断可能な第ｘ因子アナログ
JP2007506416A (ja) * 2003-09-26 2007-03-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 合成ヘパラナーゼ分子及びその使用
JP2008541742A (ja) * 2005-06-01 2008-11-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変された活性化特性を有する第ｘ凝固因子ポリペプチド
JP2009515559A (ja) * 2005-11-15 2009-04-16 ザ チルドレンズ ホスピタル オブ フィラデルフィア 止血を調節する組成物および方法
JP2009527234A (ja) * 2006-02-21 2009-07-30 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 活性化特性が変更された凝固第ｘ因子ポリペプチド
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP2012512645A (ja) * 2008-12-19 2012-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1781782T3 (da) * 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
JPH07506090A (ja) * 1992-01-03 1995-07-06 オクラホマ メディカル リサーチ ファウンデーション 組換え可溶性組織因子の発現および精製
JP2001513631A (ja) * 1997-02-27 2001-09-04 バクスター・アクチエンゲゼルシャフト 修飾されたプロテアーゼ切断部位を有するｘ因子類似体
WO2001010896A2 (en) * 1999-08-10 2001-02-15 Baxter Aktiengesellschaft Factor x analog with an improved ability to be activated
JP2005506086A (ja) * 2001-10-19 2005-03-03 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル トロンビン切断性キメラタンパク質
JP2006507806A (ja) * 2002-07-03 2006-03-09 アンスティテュ ナシオナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル トロンビン切断可能な第ｘ因子アナログ
JP2007506416A (ja) * 2003-09-26 2007-03-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 合成ヘパラナーゼ分子及びその使用
JP2008541742A (ja) * 2005-06-01 2008-11-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変された活性化特性を有する第ｘ凝固因子ポリペプチド
JP2009515559A (ja) * 2005-11-15 2009-04-16 ザ チルドレンズ ホスピタル オブ フィラデルフィア 止血を調節する組成物および方法
JP2009527234A (ja) * 2006-02-21 2009-07-30 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 活性化特性が変更された凝固第ｘ因子ポリペプチド
WO2009146183A1 (en) * 2008-04-15 2009-12-03 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP2012512645A (ja) * 2008-12-19 2012-06-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DOUGHERTY, W.G. ET AL., VIROLOGY, vol. 171, JPN6019007297, 1989, pages 356 - 364, ISSN: 0003988047 *
GALLWITZ, M. ET AL., PLOS ONE, vol. 7, JPN6017041680, 2012, pages 31756 - 1, ISSN: 0003676453 *
KOSTALLAS, G. ET AL., PLOS ONE, vol. 6, JPN6019007300, 2011, pages 16136 - 1, ISSN: 0003988044 *
LOUVAIN-QUINTARD, V.B. ET AL., J. BIOL. CHEM., vol. 280, JPN6017041676, 2005, pages 41352 - 41359, ISSN: 0003676450 *
NARDELLA, C. ET AL., BIOCHEMISTRY, vol. 43, JPN6019007293, 2004, pages 1862 - 1873, ISSN: 0003988043 *
NI, F. ET AL., J. MOL. BIOL., vol. 252, JPN6017041681, 1995, pages 656 - 671, ISSN: 0003676454 *
NIEMAN, M.T. AND SCHMAIER, A.H., BIOCHEMISTRY, vol. 46, JPN6017041673, 2007, pages 8603 - 8610, ISSN: 0003676447 *
PETRASSI, H.M. ET AL., BIOORG. MED. CHEM. LETT., vol. 15, JPN6017041674, 2005, pages 3162 - 3166, ISSN: 0003676448 *
QUADE-LYSSY, P. ET AL., J. GENET. SYNDR. GENE THER., vol. S1:013, JPN6017041675, 2012, ISSN: 0003676449 *
RUDOLPH, A.E. ET AL., THROMB. HAEMOST., vol. 88, JPN6017041678, 2002, pages 756 - 762, ISSN: 0003676451 *
SOTO, A.G. AND TREJO, J., J. BIOL. CHEM., vol. 285, JPN6017041682, 2010, pages 18781 - 18793, ISSN: 0003676455 *
VOLKEL, T. ET AL., MOL. BIOTECHNOL., vol. 29, JPN6017041679, 2005, pages 19 - 30, ISSN: 0003676452 *
WAUGH, D.S., PROTEIN EXP. PURIF., vol. 80, JPN6019007296, 2011, pages 283 - 293, ISSN: 0003988046 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019050819A (ja) * 2013-02-04 2019-04-04 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 第ｘ因子変異体
JP2019521324A (ja) * 2016-05-13 2019-07-25 ザ・スクリップス・リサーチ・インスティテュートＴｈｅ Ｓｃｒｉｐｐｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗血栓療法および止血療法のための組成物および方法

Also Published As

Publication number Publication date
CA2900010A1 (en) 2014-08-07
ES2636162T3 (es) 2017-10-05
KR101942619B1 (ko) 2019-01-25
AU2014210986A1 (en) 2015-07-23
WO2014118481A1 (fr) 2014-08-07
IL239889A0 (en) 2015-08-31
EP2951297A1 (fr) 2015-12-09
CN104995297A (zh) 2015-10-21
CN104995297B (zh) 2018-10-26
JP2019050819A (ja) 2019-04-04
EP2951297B1 (fr) 2017-05-03
DK2951297T3 (en) 2017-08-28
US20160145598A1 (en) 2016-05-26
MX2015009867A (es) 2015-10-05
FR3001729A1 (fr) 2014-08-08
US10364424B2 (en) 2019-07-30
KR20150113205A (ko) 2015-10-07
FR3001729B1 (fr) 2015-03-06

Similar Documents

Publication Publication Date Title
JP6698102B2 (ja) 凝固因子と多重特異的抗体を用いた併用療法
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
KR101841870B1 (ko) 표적화 응고 인자 및 그의 사용 방법
CN102325880B (zh) 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
US20090053185A1 (en) Coagulation factor x polypeptides with modified activation properties
US9493761B2 (en) Procoagulant molecular decoy for treating hemophilia A or B with or without inhibitor
JP2019050819A (ja) 第ｘ因子変異体
Dahlback Factor V and protein S as cofactors to activated protein C
Gailani Gene Targeting in Hemostasis, Factor XI
EP3010533B1 (fr) Facteur x depourvu de domaine gla
US20190338269A1 (en) Factor x variants
Class et al. Patent application title: Serene Protease Derivatives and Uses in the Prevention or the Treatment of Blood Coagulation Disorders Inventors: Olivier Christophe (Le Kremlin Bicetre Cedex, FR) Cecile Denis (Le Kremlin Bicetre Cedex, FR) Ghislaine Cherel (Le Kremlin Bicetre Cedex, FR) Paul Gueguen (Brest Cedex, FR) Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
WO2008059043A2 (en) Combination of coagulation factor viii with apc-resistant factor v

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181226

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20200629